Our Analysis

Team: 6

Feasibility: 6.4

Product: 6.4

Overall Rating: 6.27

Short Description: We are a privately held clinical-stage biotechnology company focusing on the development and commercialization of a revolutionary new immune therapy technology platform for the treatment of chronic viral infections, cancer and allergy.

Category: Tokens Cryptocurrency

Category: Tourism



Our Immune Therapies are designed to boost specific immune response in order to modify or control presently incurable diseases.Our proprietary Platform Technology includes a plasmid DNA-based, disease specific antigen, a nanomedicine formulation which encapsulates the plasmid DNA to closely resemble a virus, and a topical (through the skin) administration device which delivers the vaccine via dendritic cell to lymph nodes of the immune system. Our technologies support the rapid and cost-effective development of original biologic (as opposed to drugs) products. Our Lead Therapeutic Vaccine for treatment of HIV, referred to as “DermaVir”, is effective in boosting immune response which in turn kills HIV-infected cells. Our human clinical trials in Phase I, Phase I/II and Phase II have demonstrated our vaccine is capable of killing HIV-infected cells. DermaVir has an excellent safety profile similar to vaccines used in healthy adults and children. DermaVir can also be a co-treatment option if administered with antiretroviral therapy.We are raising funds in this ICO to complete the regulatory documentation needed to seek United States Food and Drug Administration (FDA) guidance on the best path to marketing approval, including Breakthrough Therapy Designation and Fast-track. Post approval our products will allow people to live better and longer lives.

We will accept ETH with the following terms: Dermavir (GIC$) Coins

- A total of 15 million Dermavir Coins are issued through the Ethereum platform.

- There will be no additional issuance of Dermavir coins in the future.

- The number of coins for sale during the Dermavir ICO are hard capped at: 10 million tokens

- We are offering investors the opportunity to obtain Dermavir coins at a cheaper rate in its early stage before it gets listed on major exchanges.

- First tier investors from 6 February to 6 March can acquire Dermavir coins for as low as $0.70 which is at a 30% discount to market price. We will make a total of 4,000,000 coins available in this round.

- Second tier investors, beginning 7 March and ending 7 April, can acquire Dermavir coins for as low as $0.80 which is at a 20% discount to market price. We will make a total of 3,000,000 coins available in this round.

- Third tier investors, beginning 8 April and ending 8 May, can acquire Dermavir coins for as low as $0.90 which is at a 10% discount to market price. We will make a total of 2,000,000 coins available in this round.

- And finally investors in the public offering, beginning 9 May and ending 9 June, can acquire Dermavir coins for $1.00. We will make a total of 1,000,000 coins available in this round.

- The ICO will commence on 6 February 2018 at 9 am (GMT)

- The ICO will end on 9 June, 2018 at 9 pm (GMT) or when the hard cap is reached.

To receive the latest ICO, STO and token sale news — including scam alerts and our exceptional, original journalism — sign up for our newsletter.

Sorry, error.
Thank you.
ICO Ranker
Login/Register access is temporary disabled